These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26997442)

  • 1. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
    Schönleben F; Qiu W; Allendorf JD; Chabot JA; Remotti HE; Su GH
    J Gastrointest Surg; 2009 Aug; 13(8):1510-6. PubMed ID: 19440799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma.
    Westgaard A; Tafjord S; Farstad IN; Cvancarova M; Eide TJ; Mathisen O; Clausen OP; Gladhaug IP
    BMC Cancer; 2008 Jun; 8():170. PubMed ID: 18547417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
    Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
    PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
    Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
    J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
    Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors.
    Kinugasa H; Kanzaki H; Tanaka T; Yamamoto S; Yamasaki Y; Nouso K; Ichimura K; Nakagawa M; Mitsuhashi T; Okada H
    Clin Transl Gastroenterol; 2021 Nov; 12(11):e00424. PubMed ID: 34797780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the two histological subtypes of ampullary adenocarcinoma: a retrospective study.
    Xu ZY; Guan J; Zhang ZY; Liu DW; Li XD; Zhou ZQ
    Cir Cir; 2024; 92(2):159-164. PubMed ID: 38782386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation.
    Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
    Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater.
    de Paiva Haddad LB; Patzina RA; Penteado S; Montagnini AL; da Cunha JE; Machado MC; Jukemura J
    J Gastrointest Surg; 2010 Apr; 14(4):719-28. PubMed ID: 20107918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
    Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
    PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
    Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
    Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Predictors for Intestinal and Pancreatobiliary Types of Adenocarcinoma of The Ampulla of Vater.
    da Silveira Santos JPL; Machado CJ; Junior EP; Rodrigues JBSR; Vidigal PT; Resende V
    J Gastrointest Surg; 2018 Jul; 22(7):1171-1178. PubMed ID: 29736668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of stem cell/ epithelial-mesenchymal transition markers in periampullary/pancreatic cancers: FGFR1 is a promising prognostic marker.
    Chong Y; Thakur N; Paik KY; Lee EJ; Kang CS
    BMC Cancer; 2020 Mar; 20(1):216. PubMed ID: 32171280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.
    Kim MH; Jang M; Kim H; Lee WJ; Kang CM; Choi HJ
    Cancer Immunol Immunother; 2019 Mar; 68(3):443-454. PubMed ID: 30604042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Targets and Therapies for Ampullary Cancer.
    Patel MA; Kratz JD; Carlson AS; Ascencio YO; Kelley BS; LoConte NK
    J Natl Compr Canc Netw; 2024 Jan; 22(2D):. PubMed ID: 38181507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
    Myers MB; Banda M; McKim KL; Wang Y; Powell MJ; Parsons BL
    Neoplasia; 2016 Apr; 18(4):253-63. PubMed ID: 27108388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
    Parsons BL; McKim KL; Myers MB
    Environ Mol Mutagen; 2017 Aug; 58(7):466-476. PubMed ID: 28755461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of Small-Bowel Adenocarcinoma.
    Schrock AB; Devoe CE; McWilliams R; Sun J; Aparicio T; Stephens PJ; Ross JS; Wilson R; Miller VA; Ali SM; Overman MJ
    JAMA Oncol; 2017 Nov; 3(11):1546-1553. PubMed ID: 28617917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.